drugset
drugset / Trial / NCT06256055

Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors

NCT06256055 ↗

Phase 1 Unknown 24 enrolled UTC Therapeutics Inc. Peking University Cancer Hospital & Institute · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a first-in-human, single-arm, open-label, dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics, immunogenicity and preliminary efficacy of UCMYM802 (Circular mRNA encoding Anti-Mesothelin CAR-T) injection in patients with Mesothelin-positive advanced malignant solid tumors.

Timeline

Start
2024-03-05
Primary completion
2025-03
Completion
2025-04

Drugs

EvaluationDrugModalityDoseRoute
Subject UCMYM802 Cell therapy 1e+08 cells Intravenous
Subject UCMYM802 Cell therapy 2e+09 cells Intravenous

Indications

bile duct cancer female breast carcinoma malignant mesothelioma malignant pancreatic neoplasm ovarian cancer rectal cancer